ATE442850T1 - Kappa-opioid-rezeptor-liganden - Google Patents

Kappa-opioid-rezeptor-liganden

Info

Publication number: ATE442850T1
Authority: AT; Austria
Prior art keywords: opioid receptor; kappa opioid; receptor ligands; antagonists; kappa
Prior art date: 2001-02-01

Application number

AT02704144T

Other languages

English (en)

Inventor

F Carroll

James Thomas

S Mascarella

Original Assignee

Res Triangle Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-01

Filing date

2002-02-01

Publication date

2009-10-15

2002-02-01 Application filed by Res Triangle Inst filed Critical Res Triangle Inst

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE442850T1 publication Critical patent/ATE442850T1/de

Links

102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 3
108020001588 κ-opioid receptors Proteins 0.000 title abstract 3
239000003446 ligand Substances 0.000 title 1
206010013663 drug dependence Diseases 0.000 abstract 2
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
208000003698 Heroin Dependence Diseases 0.000 abstract 1
229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
201000006145 cocaine dependence Diseases 0.000 abstract 1
229960002069 diamorphine Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

AT02704144T 2001-02-01 2002-02-01 Kappa-opioid-rezeptor-liganden ATE442850T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/774,566 US6559159B2 (en)	2001-02-01	2001-02-01	Kappa opioid receptor ligands
PCT/US2002/001231 WO2002060445A1 (en)	2001-02-01	2002-02-01	Kappa opioid receptor ligands

Publications (1)

Publication Number	Publication Date
ATE442850T1 true ATE442850T1 (de)	2009-10-15

Family

ID=25101637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02704144T ATE442850T1 (de)	2001-02-01	2002-02-01	Kappa-opioid-rezeptor-liganden

Country Status (9)

Country	Link
US (1)	US6559159B2 (de)
EP (1)	EP1363629B1 (de)
JP (1)	JP4275945B2 (de)
AT (1)	ATE442850T1 (de)
AU (1)	AU2002237844B2 (de)
CA (1)	CA2436409C (de)
DE (1)	DE60233720D1 (de)
ES (1)	ES2330727T3 (de)
WO (1)	WO2002060445A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7189737B2 (en) *	1991-08-09	2007-03-13	Research Triangle Institute	Cocaine receptor binding ligands
US6538010B1 (en) *	2000-11-08	2003-03-25	Research Triangle Institute	Compounds and methods for promoting smoking cessation
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
US7056930B2 (en)	2003-04-14	2006-06-06	Pfizer Inc.	2-Azabicyclo[3.3.1]nonane derivatives
US7201920B2 (en)	2003-11-26	2007-04-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of opioid containing dosage forms
PT1765292T (pt)	2004-06-12	2017-12-29	Collegium Pharmaceutical Inc	Formulações de fármacos dissuasoras de abuso
US20080045610A1 (en) *	2004-09-23	2008-02-21	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) *	2004-09-23	2006-03-30	Alexander Michalow	Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060110327A1 (en) *	2004-11-24	2006-05-25	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) *	2004-11-24	2007-10-04	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) *	2004-11-24	2006-08-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) *	2004-11-24	2008-06-26	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US7872023B2 (en) *	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
US7399762B2 (en) *	2005-04-25	2008-07-15	Research Triangle Institute	Opioid receptor agonist compounds and their use in treatment of pain
US7476679B2 (en) *	2005-07-26	2009-01-13	Research Triangle Institute	Octahydroisoquinoline compounds as opioid receptor modulators
EP1928437A2 (de)	2005-08-26	2008-06-11	Braincells, Inc.	Neurogenese mittels muscarinrezeptormodulation
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US8329744B2 (en) *	2005-11-02	2012-12-11	Relmada Therapeutics, Inc.	Methods of preventing the serotonin syndrome and compositions for use thereof
WO2007056142A2 (en) *	2005-11-02	2007-05-18	Theraquest Biosciences, Llc	Methods of preventing the serotonin syndrome and compositions for use therefor
WO2008134071A1 (en) *	2007-04-26	2008-11-06	Theraquest Biosciences, Inc.	Multimodal abuse resistant extended release formulations
US20090082466A1 (en) *	2006-01-27	2009-03-26	Najib Babul	Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
EP2068872A1 (de)	2006-09-08	2009-06-17	Braincells, Inc.	Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8748448B2 (en)	2007-10-18	2014-06-10	Aiko Biotechnology	Combination analgesic employing opioid agonist and neutral antagonist
EP2214672B1 (de) *	2007-10-18	2012-10-17	Aiko Biotechnology	Kombinationsanalgetikum mit einem opioid und einem neutralen antagonisten
US8048895B2 (en) *	2008-04-18	2011-11-01	Research Triangle Institute	Kappa opioid receptor ligands
WO2009156889A1 (en) *	2008-06-25	2009-12-30	Pfizer Inc.	Diaryl compounds and uses thereof
BRPI0921725A2 (pt)	2008-10-30	2016-01-05	Grüenthal GmbH	formas de dosagem potentes do tapentadol
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP3064064A1 (de) *	2009-09-30	2016-09-07	Acura Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur abschreckung vor missbrauch
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2787037C (en)	2010-02-24	2018-04-10	Research Triangle Institute	Arylpiperazine opioid receptor antagonists
HUE034955T2 (en)	2010-12-22	2018-03-28	Purdue Pharma Lp	Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
MX366159B (es)	2012-11-30	2019-07-01	Acura Pharmaceuticals Inc	Liberacion autorregulada de ingrediente farmaceutico activo.
US9283196B1 (en)	2013-01-30	2016-03-15	MediSynergics, LLC	Cycloalkyl-diamines for CNS disorders
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
AU2015237721B2 (en)	2014-03-26	2018-04-26	Sun Pharma Advanced Research Company Ltd.	Abuse deterrent immediate release coated reservoir solid dosage form
WO2017040607A1 (en)	2015-08-31	2017-03-09	Acura Pharmaceuticals, Inc.	Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
EP3723751A4 (de) *	2017-12-08	2021-07-07	The Rockefeller University	Pyrano[3,4-b]pyrazin-kappa-opioid-rezeptorliganden zur behandlung von sucht, pruritus, schmerzen und entzündung
US11352365B2 (en)	2018-03-19	2022-06-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4278797A (en)	1979-03-12	1981-07-14	Eli Lilly And Company	Intermediates to phenylmorphans and method of preparation thereof

2001
- 2001-02-01 US US09/774,566 patent/US6559159B2/en not_active Expired - Fee Related
2002
- 2002-02-01 EP EP02704144A patent/EP1363629B1/de not_active Expired - Lifetime
- 2002-02-01 CA CA2436409A patent/CA2436409C/en not_active Expired - Fee Related
- 2002-02-01 DE DE60233720T patent/DE60233720D1/de not_active Expired - Lifetime
- 2002-02-01 ES ES02704144T patent/ES2330727T3/es not_active Expired - Lifetime
- 2002-02-01 AU AU2002237844A patent/AU2002237844B2/en not_active Ceased
- 2002-02-01 JP JP2002560637A patent/JP4275945B2/ja not_active Expired - Fee Related
- 2002-02-01 WO PCT/US2002/001231 patent/WO2002060445A1/en not_active Ceased
- 2002-02-01 AT AT02704144T patent/ATE442850T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1363629B1 (de)	2009-09-16
WO2002060445A1 (en)	2002-08-08
CA2436409A1 (en)	2002-08-08
CA2436409C (en)	2010-12-07
US20020143145A1 (en)	2002-10-03
US6559159B2 (en)	2003-05-06
ES2330727T3 (es)	2009-12-15
AU2002237844B2 (en)	2006-03-16
DE60233720D1 (de)	2009-10-29
JP2004520383A (ja)	2004-07-08
EP1363629A1 (de)	2003-11-26
EP1363629A4 (de)	2004-03-31
JP4275945B2 (ja)	2009-06-10

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE442850T1 (de)	2009-10-15	Kappa-opioid-rezeptor-liganden
ATE389404T1 (de)	2008-04-15	Kappa-opioid-rezeptor-liganden
AU2003299747A8 (en)	2004-07-22	Tumor killing/tumor regression using cxcr4 antagonists
PL1957539T3 (pl)	2013-08-30	Ludzkie przeciwciała monoklonalne przeciwko białku kinazy tyrozynowej 7 (PTK7) i ich zastosowanie
AP2004002982A0 (en)	2004-03-31	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
AP2004003002A0 (en)	2004-03-31	azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
MXPA03008739A (es)	2003-12-11	Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
EP1983002A3 (de)	2009-03-11	Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008013948A3 (en)	2009-02-26	Tyrosine phosphorylation sites
WO2008054597A3 (en)	2008-10-09	Tyrosine phosphorylation sites
DE50011178D1 (de)	2005-10-20	Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE10292400T1 (de)	2003-07-03	Kraftstoffbehandlungsbehälter
DE60324431D1 (de)	2008-12-11	Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
WO2008013934A8 (en)	2008-03-13	Tyrosine phosphorylation sites
EP1983003A3 (de)	2009-03-11	Tyrosinphosphorylationsstellen und spezifische Antikörper
ZA200307475B (en)	2005-01-03	Carbamate compounds for use in the treatment of pain.
IL139217A0 (en)	2001-11-25	Monoclonal antibodies to the human ldl receptor, their production and use
HUP0300339A3 (en)	2009-01-28	Use of fulvestrant in the treatment of resistant breast cancer
ATE556071T1 (de)	2012-05-15	Kappa-opioidrezeptor-liganden
EP1782944A4 (de)	2010-05-05	Hammer und drehformpressmaschine damit
ZA200501288B (en)	2005-09-05	Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
EP1988103A3 (de)	2009-03-11	Tyrosinphosphorylationsstellen und spezifische Antikörper
EP2292666A3 (de)	2011-06-08	Neoplasma-spezifische Antikörper und deren Verwendungen
PL369402A1 (en)	2005-04-18	Use for the treatment of gastroesophageal reflux disease
NO20030593D0 (no)	2003-02-06	Fremgangsmåter for behandling av cancer og smerten forbundet derved ved å anvende endotelinantagonister